One of the HDAC inhibitors, vorinostat, has been approved by FDA for treating cutaneous T-cell lymphoma (CTCL) for patients with progressive, persistent, or recurrent disease on or following two systemic therapies. This evidence concerns the gene HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma.